Introduction
Newborn screening is the most widely utilized form of genetic testing in the United States. Virtually all neonates, over four million per year, undergo a "heel stick" to provide a blood specimen that is then screened for between 2 and 10 genetic and nongenetic conditions. The combined number of infants screened in the newbom period and the number of neonatal screening tests performed far exceed those for any other type of genetic testing.
Despite the universally acknowl- '7,11-13 Public participation in medical policy-making also has important potential benefits to scientists, physicians, and public health experts. Consumer representatives on committees and institutional review boards provide unique perspectives, while their absence creates the appearance, if not the reality, of elitism. Exclusion of relevant communities from policy-making can alienate presumed beneficiaries of genetic services. This was the case for some of the early sickle cell heterozygote screening programs. '4"15 The first widely applied screening test for a genetic condition, newborn screening for phenylketonuria, began in the early 1960s, before the consumer rights movement. Over the past 3 decades, a number of movements, including the medical consumerism, women's health, patient's rights, and disability rights movements, have begun to change traditional medical practice and policy-making. ' Excellent surveys of state newbornscreening program policies have been published.'6"7 However, none have addressed the issue of public participation in policy-making. The goals of our study were (1) to ascertain information on the current newborn-screening tests performed, (2) to assess the level of public participation in the development of newborn-screening policy and practice, and (3) to assess the involvement and rights of parents as consumers in newborn-screening programs. There are also important technical issues in newborn screening for which policies must be formulated.42 These include choosing methodologies and ensuring laboratory quality control. Our results indicate that there is little public participation in decision making about technical issues. Responses to our questions suggested that many experts in newborn screening perceive the public as unable to understand technical issues sufficiently to be involved in policymaking. In contrast, it is a fundamental assumption of the US legal system that the general public can understand and utilize complex information to make significant decisions, such as when jurors consider highly technical forensic DNA data to reach verdicts. There are also examples of lay citizens assisting in the formulation of sound public and medical policies requiring an understanding of complex scientific and medical information. [55] [56] [57] [58] Our study found that the public has involvement in formulating policies regarding follow-up for individuals with metabolic and/or congenital disorders in 27 out of 51 programs. It should also be noted that there is tremendous variation in follow-up from state to state; in some programs, follow-up refers to completion of diagnostic testing after a positive screen, while other programs provide counseling and expensive dietary treatment. 47 
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